AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's rules on approving new medicines as well as a row over drug prices.

On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City.

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the discovery of novel oral therapies for chronic diseases. The partnership, ...

AstraZeneca plc, a British-Swedish multinational pharmaceutical and biotechnology company, has entered into a strategic partnership agreement with China's CSPC Pharmaceuticals Group Limited to develop ...

AstraZeneca has signed an AI-led research agreement with China’s CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

Under a strategic research collaboration between Astrazeneca and CSPC Pharmaceuticals, both the companies will join hands to advance the discovery and development of novel oral candidates. Under the ...

CSPC is headquartered in China's Hebei Province. AstraZeneca, whose own expanding HQ is at the Cambridge Biomedical Campus, only recently revealed plans to invest $2.5bn in a new research flagship in ...

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance ...

CSPC will conduct the research using their AI-driven drug discovery platform, which harnesses artificial intelligence to analyze the binding patterns of target proteins with compound molecules, ...